AbbVie announced the launch of Creon (pancrelipase) 36,000 lipase-unit delayed-release capsules for the treatment of patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, ...
NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON ® (pancrelipase) Delayed-Release Capsules is commercially available in ...
CREON (Lipase, amylase, protease) e-c minimicrospheres in capsules by AbbVie Solvay Pharmaceuticals has made available Creon (pancrelipase) delayed-release capsules, a "zero-overfill" pancreatic ...
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) ...
Add Yahoo as a preferred source to see more of our stories on Google. Wes Streeting says he is "extremely sorry" patients who need medication for pancreatic insufficiency are being affected by ...
May 4, 2010 (UPDATED May 5, 2010) — The US Food and Drug Administration (FDA) has granted specific approval of pancrelipase delayed-release capsules (Creon; Abbott Labs) for the treatment of exocrine ...
International Journal of Pharmceutics: In Vitro: The dissolution characteristics of five capsules (Next Generation Enteric [NGE], Vcaps® Enteric [VCE], VCE DUOCAP® [VCE/VCE] system, Hard Gelatin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results